Klaus Fink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Klaus Fink has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Manfred Göthert
Institut für Pharmakologie und Toxikologie, Universitätsklinikum Bonn, Reuterstrasse 2b, 53113 Bonn, Germany
3 shared publicationsHans Clusmann
Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany
2 shared publicationsWolfgang P. Meder
Institut für Pharmakologie und Toxikologie, Universitätsklinikum Bonn, Reuterstrasse 2b, 53113 Bonn, Germany
2 shared publicationsC. Weissbrich
Department of Pharmacology, University of Bonn, Bonn and
1 shared publicationDavid J Dooley
22Department of Neuroscience Therapeutics, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co., Ann Arbor, Michigan, MI 48105, U.S.A.
1 shared publicationDavid J. Dooley
1 shared publication
Latest Publications
- 29 November 2007
- Published by Elsevier in Pharmacological Reviews
- Vol. 59 (4) , 360-417
5-HT Receptor Regulation of Neurotransmitter Release
Serotoninergic neurons in the central nervous system impinge on many other neurons and modulate their neurotransmitter release. This review focuses on 1) the function of presynaptic 5-hydroxytryptamine (5-HT) heteroreceptors on axon terminals of central cholinergic, dopaminergic, noradrenergic, or GABAergic neurons and 2) the role of GABAergic interneurons expressing 5-HT heteroreceptors in the regulation of acetylcholine, dopamine, or noradrenaline release. In vitro studies on slices or synaptosomes and in vivo microdialysis experiments have shown that 5-HT(1A), 5-HT(1B), 5-HT(2A), 5-HT(2C), 5-HT(3), and/or 5-HT(4) heteroreceptors mediate this modulation. 5-HT(1B) receptors on neocortical cholinergic, striatal dopaminergic, or hippocampal GABAergic axon terminals are examples for release-inhibiting 5-HT heteroreceptors; 5-HT(3) receptors on hippocampal GABAergic or 5-HT(4) receptors on hippocampal cholinergic axon terminals are examples for release-facilitating 5-HT heteroreceptors. GABA released from GABAergic interneurons upon activation of facilitatory 5-HT receptors, e.g., 5-HT(2A) or 5-HT(3) receptors, mediates inhibition of the release of other neurotransmitters such as prefrontal neocortical dopamine or neocortical acetylcholine release, respectively. Conversely, attenuated GABA release in response to activation of inhibitory 5-HT heteroreceptors, e.g., 5-HT(1A) or 5-HT(1B) receptors on GABAergic interneurons is involved in paradoxical facilitation of hippocampal acetylcholine and striatal dopamine release, respectively. Such 5-HT heteroreceptors are considered potential targets for appropriate 5-HT receptor ligands which, by enhancing the release of a relevant neurotransmitter, can compensate for its hypothesized deficiency in distinct brain areas. Examples for such deficiencies are the impaired release of hippocampal or neocortical acetylcholine, striatal dopamine, and hippocampal or neocortical noradrenaline in disorders such as Alzheimer's disease, Parkinson's disease, and major depression, respectively.
- 29 November 2007
- Published by Elsevier in Pharmacological Reviews
- Vol. 59 (4) , 360-417
5-HT Receptor Regulation of Neurotransmitter Release
Serotoninergic neurons in the central nervous system impinge on many other neurons and modulate their neurotransmitter release. This review focuses on 1) the function of presynaptic 5-hydroxytryptamine (5-HT) heteroreceptors on axon terminals of central cholinergic, dopaminergic, noradrenergic, or GABAergic neurons and 2) the role of GABAergic interneurons expressing 5-HT heteroreceptors in the regulation of acetylcholine, dopamine, or noradrenaline release. In vitro studies on slices or synaptosomes and in vivo microdialysis experiments have shown that 5-HT(1A), 5-HT(1B), 5-HT(2A), 5-HT(2C), 5-HT(3), and/or 5-HT(4) heteroreceptors mediate this modulation. 5-HT(1B) receptors on neocortical cholinergic, striatal dopaminergic, or hippocampal GABAergic axon terminals are examples for release-inhibiting 5-HT heteroreceptors; 5-HT(3) receptors on hippocampal GABAergic or 5-HT(4) receptors on hippocampal cholinergic axon terminals are examples for release-facilitating 5-HT heteroreceptors. GABA released from GABAergic interneurons upon activation of facilitatory 5-HT receptors, e.g., 5-HT(2A) or 5-HT(3) receptors, mediates inhibition of the release of other neurotransmitters such as prefrontal neocortical dopamine or neocortical acetylcholine release, respectively. Conversely, attenuated GABA release in response to activation of inhibitory 5-HT heteroreceptors, e.g., 5-HT(1A) or 5-HT(1B) receptors on GABAergic interneurons is involved in paradoxical facilitation of hippocampal acetylcholine and striatal dopamine release, respectively. Such 5-HT heteroreceptors are considered potential targets for appropriate 5-HT receptor ligands which, by enhancing the release of a relevant neurotransmitter, can compensate for its hypothesized deficiency in distinct brain areas. Examples for such deficiencies are the impaired release of hippocampal or neocortical acetylcholine, striatal dopamine, and hippocampal or neocortical noradrenaline in disorders such as Alzheimer's disease, Parkinson's disease, and major depression, respectively.
- 1 November 2002
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 366 (5) , 458-463
Ca 2+ entry via P/Q-type Ca 2+ channels and the Na + /Ca 2+ exchanger in rat and human neocortical synaptosomes
Rat or human neocortical synaptosomes were used to study the role of voltage-gated Ca2+ channels and the Na+/Ca2+ exchanger in 45Ca2+ influx into nerve terminals. K+ depolarization-induced 45Ca2+ influx through voltage-gated Ca2+ channels into rat or human synaptosomes was completely blocked by mibefradil 30 µM or Cd2+ 100 µM but was not affected by tetrodotoxin 1 µM. It was reduced by ω-agatoxin IVA 0.2 µM by 68% in synaptosomes of either species, whereas ω-conotoxin GVIA 0.1 µM and nifedipine 1 µM had no effect. Veratridine-induced 45Ca2+ entry into rat neocortical synaptosomes was completely blocked by mibefradil 30 µM, reduced by 80% by Cd2+ 100 µM, by 90% by tetrodotoxin 1 µM and by 53% by ω-agatoxin IVA 0.2 µM but not by ω-conotoxin GVIA 0.1 µM or nifedipine 1 µM. Na+/Ca2+ exchanger-mediated 45Ca2+ uptake into rat neocortical synaptosomes evoked by replacement of Na+ by choline+ in the incubation buffer was reduced by KB-R7943 (3–50 µM), an inhibitor of the Na+/Ca2+ exchanger, in a concentration-dependent manner (maximal inhibition by 46% at 50 µM; IC23%=7.1 µM). Mibefradil also inhibited the Na+/Ca2+ exchanger-mediated Ca2+ uptake, although at 3.7 times lower potency (IC23%=26 µM). It is concluded that in rat and human neocortical nerve terminals Ca2+ entry is mediated under physiological conditions by P/Q-type, but not by N- or L-type Ca2+ channels or the Na+/Ca2+ exchanger. If the cytosolic Na+ concentration is increased, Ca2+ is also taken up via the Na+/Ca2+ exchanger. In addition to the ability of mibefradil to block all voltage-operated Ca2+ channels, this drug is a low potency inhibitor of the Na+/Ca2+ exchanger.
- 1 November 2002
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 366 (5) , 458-463
Ca 2+ entry via P/Q-type Ca 2+ channels and the Na + /Ca 2+ exchanger in rat and human neocortical synaptosomes
Rat or human neocortical synaptosomes were used to study the role of voltage-gated Ca2+ channels and the Na+/Ca2+ exchanger in 45Ca2+ influx into nerve terminals. K+ depolarization-induced 45Ca2+ influx through voltage-gated Ca2+ channels into rat or human synaptosomes was completely blocked by mibefradil 30 µM or Cd2+ 100 µM but was not affected by tetrodotoxin 1 µM. It was reduced by ω-agatoxin IVA 0.2 µM by 68% in synaptosomes of either species, whereas ω-conotoxin GVIA 0.1 µM and nifedipine 1 µM had no effect. Veratridine-induced 45Ca2+ entry into rat neocortical synaptosomes was completely blocked by mibefradil 30 µM, reduced by 80% by Cd2+ 100 µM, by 90% by tetrodotoxin 1 µM and by 53% by ω-agatoxin IVA 0.2 µM but not by ω-conotoxin GVIA 0.1 µM or nifedipine 1 µM. Na+/Ca2+ exchanger-mediated 45Ca2+ uptake into rat neocortical synaptosomes evoked by replacement of Na+ by choline+ in the incubation buffer was reduced by KB-R7943 (3–50 µM), an inhibitor of the Na+/Ca2+ exchanger, in a concentration-dependent manner (maximal inhibition by 46% at 50 µM; IC23%=7.1 µM). Mibefradil also inhibited the Na+/Ca2+ exchanger-mediated Ca2+ uptake, although at 3.7 times lower potency (IC23%=26 µM). It is concluded that in rat and human neocortical nerve terminals Ca2+ entry is mediated under physiological conditions by P/Q-type, but not by N- or L-type Ca2+ channels or the Na+/Ca2+ exchanger. If the cytosolic Na+ concentration is increased, Ca2+ is also taken up via the Na+/Ca2+ exchanger. In addition to the ability of mibefradil to block all voltage-operated Ca2+ channels, this drug is a low potency inhibitor of the Na+/Ca2+ exchanger.
- 1 September 2002
- Published by Springer Nature in Amino Acids
- Vol. 23 (1) , 325-329
Effects of cytoskeletal modi?cations on Ca 2+ in?ux after cerebral ischemia
The fungal toxin cytochalasin D as well as endogenous gelsolin depolymerize filamentous actin which may induce dynamic uncoupling of membrane ion channels. In vitro application of cytochalasin D reduced NMDA-induced [3H]noradrenaline release from mouse brain neocortical slices by 38%. In gsn deficient neocortical synaptosomes [Ca2+]i increase in response to K+ (30 mM) depolarization was 33% higher than in wild-type. After transient focal cerebral ischemia K+-induced [Ca2+]i increase in neocortical synaptosomes was 56% lower than in synaptosomes prepared from the non-ischemic contralateral hemisphere. After in vivo pretreatment with cytochalasin D 10 min before MCA occlusion K+-induced [Ca2+]i increase in synaptosomes in vitro prepared 1 h after reperfusion from the ischemic hemisphere was only 25% lower than in contralateral synaptosomes, while cytochalasin D pretreatment in vivo did not reduce K+-induced [Ca2+]i increase in vitro. Hence, presynaptic Ca2+ influx and subsequently neuronal vulnerability are attenuated by increased and are aggravated by decreased F-actin depolymerization.
- 1 September 2002
- Published by Springer Nature in Amino Acids
- Vol. 23 (1) , 325-329
Effects of cytoskeletal modi?cations on Ca 2+ in?ux after cerebral ischemia
The fungal toxin cytochalasin D as well as endogenous gelsolin depolymerize filamentous actin which may induce dynamic uncoupling of membrane ion channels. In vitro application of cytochalasin D reduced NMDA-induced [3H]noradrenaline release from mouse brain neocortical slices by 38%. In gsn deficient neocortical synaptosomes [Ca2+]i increase in response to K+ (30 mM) depolarization was 33% higher than in wild-type. After transient focal cerebral ischemia K+-induced [Ca2+]i increase in neocortical synaptosomes was 56% lower than in synaptosomes prepared from the non-ischemic contralateral hemisphere. After in vivo pretreatment with cytochalasin D 10 min before MCA occlusion K+-induced [Ca2+]i increase in synaptosomes in vitro prepared 1 h after reperfusion from the ischemic hemisphere was only 25% lower than in contralateral synaptosomes, while cytochalasin D pretreatment in vivo did not reduce K+-induced [Ca2+]i increase in vitro. Hence, presynaptic Ca2+ influx and subsequently neuronal vulnerability are attenuated by increased and are aggravated by decreased F-actin depolymerization.
- 1 February 2002
- Published by Elsevier in Neuropharmacology
- Vol. 42 (2) , 229-236
Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex
- 1 February 2002
- Published by Elsevier in Neuropharmacology
- Vol. 42 (2) , 229-236
Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex
- 1 June 2000
- Published by Wiley in British Journal of Pharmacology
- Vol. 130 (4) , 900-906
Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices
Cytosolic calcium ion concentrations ([Ca2+]i) were measured in rat neocortical synaptosomes using fura‐2, and depolarization of synaptosomal membranes was induced by K+ (30 mM). The release of the endogenous excitatory amino acids glutamate and aspartate was evoked by K+ (50 mM) and determined by HPLC. The release of [3H]‐noradrenaline from rat neocortical synaptosomes or slices was evoked by K+ (15 and 25 mM) and measured by liquid scintillation counting. Gabapentin produced a concentration‐dependent inhibition of the K+‐induced [Ca2+]i increase in synaptosomes (IC50=14 μM; maximal inhibition by 36%). The inhibitory effect of gabapentin was abolished in the presence of the P/Q‐type Ca2+ channel blocker ω‐agatoxin IVA, but not by the N‐type Ca2+ channel antagonist ω‐conotoxin GVIA. Gabapentin (100 μM) decreased the K+‐evoked release of endogenous aspartate and glutamate in neocortical slices by 16 and 18%, respectively. Gabapentin reduced the K+‐evoked [3H]‐noradrenaline release in neocortical slices (IC50=48 μM; maximal inhibition of 46%) but not from synaptosomes. In the presence of the AMPA receptor antagonists 6‐cyano‐7‐nitroquinoxaline‐2,3‐dione (CNQX) and 2,3‐dioxo‐6‐nitro‐1,2,3,4‐tetrahydro[f]quinoxaline‐7‐sulphonamide (NBQX), gabapentin did not reduce [3H]‐noradrenaline release. Gabapentin did, however, cause inhibition in the presence of the NMDA receptor antagonist DL‐(E)‐2‐amino‐4‐methyl‐5‐phosphono‐3‐pentanoic acid (CGP 37849). Gabapentin is concluded to reduce the depolarization‐induced [Ca2+]i increase in excitatory amino acid nerve terminals by inhibiting P/Q‐type Ca2+ channels; this decreased Ca2+ influx subsequently attenuates K+‐evoked excitatory amino acid release. The latter effect leads to a reduced activation of AMPA receptors which contribute to K+‐evoked noradrenaline release from noradrenergic varicosities, resulting in an indirect inhibition of noradrenaline release. British Journal of Pharmacology (2000) 130, 900–906; doi:10.1038/sj.bjp.0703380
- 1 June 2000
- Published by Wiley in British Journal of Pharmacology
- Vol. 130 (4) , 900-906
Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices
Cytosolic calcium ion concentrations ([Ca2+]i) were measured in rat neocortical synaptosomes using fura‐2, and depolarization of synaptosomal membranes was induced by K+ (30 mM). The release of the endogenous excitatory amino acids glutamate and aspartate was evoked by K+ (50 mM) and determined by HPLC. The release of [3H]‐noradrenaline from rat neocortical synaptosomes or slices was evoked by K+ (15 and 25 mM) and measured by liquid scintillation counting. Gabapentin produced a concentration‐dependent inhibition of the K+‐induced [Ca2+]i increase in synaptosomes (IC50=14 μM; maximal inhibition by 36%). The inhibitory effect of gabapentin was abolished in the presence of the P/Q‐type Ca2+ channel blocker ω‐agatoxin IVA, but not by the N‐type Ca2+ channel antagonist ω‐conotoxin GVIA. Gabapentin (100 μM) decreased the K+‐evoked release of endogenous aspartate and glutamate in neocortical slices by 16 and 18%, respectively. Gabapentin reduced the K+‐evoked [3H]‐noradrenaline release in neocortical slices (IC50=48 μM; maximal inhibition of 46%) but not from synaptosomes. In the presence of the AMPA receptor antagonists 6‐cyano‐7‐nitroquinoxaline‐2,3‐dione (CNQX) and 2,3‐dioxo‐6‐nitro‐1,2,3,4‐tetrahydro[f]quinoxaline‐7‐sulphonamide (NBQX), gabapentin did not reduce [3H]‐noradrenaline release. Gabapentin did, however, cause inhibition in the presence of the NMDA receptor antagonist DL‐(E)‐2‐amino‐4‐methyl‐5‐phosphono‐3‐pentanoic acid (CGP 37849). Gabapentin is concluded to reduce the depolarization‐induced [Ca2+]i increase in excitatory amino acid nerve terminals by inhibiting P/Q‐type Ca2+ channels; this decreased Ca2+ influx subsequently attenuates K+‐evoked excitatory amino acid release. The latter effect leads to a reduced activation of AMPA receptors which contribute to K+‐evoked noradrenaline release from noradrenergic varicosities, resulting in an indirect inhibition of noradrenaline release. British Journal of Pharmacology (2000) 130, 900–906; doi:10.1038/sj.bjp.0703380